IRMD Earnings Prediction
The chart below shows how IRMD performed 10 days before and after its earnings report, based on data from the past quarters. Typically, IRMD sees a -2.28% change in stock price 10 days leading up to the earnings, and a -2.22% change 10 days following the report. On the earnings day itself, the stock moves by +1.71%. This data can give you a slight idea of what to expect for the next quarter's release.
IRMD Key Earning Data
2024/Q4
Year Over Year
Quarter Over Quarter
Total Revenue
18.33M
11.04%
2.21%
Gross Margin
77.44%
-0.44%
-0.90%
Operating Margin
31.59%
-11.71%
0.64%
Net Margin
27.55%
-10.26%
0.77%
EPS
0.40
0.00%
5.26%
No Data Available
IRMD Earnings Analysis
iRadimed Corporation Corporation (IRMD.O) Earnings Conference Call
Positive
Record Revenue Increase: 1. Record Revenue Growth: IRadimed reported revenue of $18.3 million for Q3 2024, marking an 11% increase compared to the same quarter last year.
Gross Profit Margin Analysis: 2. Strong Gross Profit Margin: The company achieved a gross profit margin of 77.4% in Q3 2024, slightly below the previous year's 77.8%, reflecting continued strength in domestic revenue.
Cash Flow Surge: 3. Significant Cash Flow Improvement: Cash from operations surged to $9.1 million in Q3 2024, up from $1.4 million in the same period last year, demonstrating improved working capital management.
Disposable and Service Revenue Growth: 4. Increased Revenue from Disposables and Services: Revenue from disposables and services rose by 12% to $4.7 million in Q3 2024, contributing positively to overall revenue growth.
Earnings Guidance Increase: 5. Raised Earnings Guidance: The company raised its full-year GAAP diluted earnings per share guidance to a range of $1.49 to $1.52, up from the previous guidance of $1.37 to $1.47.
Negative
Rising Operating Expenses: 1. Increased Operating Expenses: Operating expenses rose to $8.4 million, or 46% of revenue, compared to $6.9 million, or 42% of revenue, in Q3 2023, indicating a significant increase in costs relative to revenue growth.
Operating Income Decline: 2. Decline in Operating Income: Operating income slightly decreased from $5.9 million in Q3 2023 to $5.8 million in Q3 2024, despite an 11% increase in revenue, reflecting pressure on profitability.
Consistent Net Income: 3. Stable Net Income: Net income remained unchanged at $0.40 per diluted share for Q3 2024, the same as in Q3 2023, indicating no growth in earnings despite increased revenue.
Increased Tax Expense: 4. Higher Tax Expense: The effective tax rate increased to 21.3% in Q3 2024 from 20.9% in Q3 2023, resulting in a higher tax expense of approximately $1.4 million, which could impact net income.
Revenue Dip Anticipation: 5. Potential Revenue Dip Anticipated: The company expects a dip in revenue from the old pump as they transition to the new pump, which may affect sales performance in the upcoming quarters.
IRMD FAQs
How does IRMD typically perform around its earnings report dates?
Is IRADIMED CORPORATION (IRMD) Q3 2024 Earnings Call Summary positive or negative?
How can historical earnings data help predict future stock performance?
IRMD Earning Call Sentiment
IRADIMED CORPORATION (IRMD) Q3 2024 Earnings Call Transcript
1.0x
00:00
00:00
IRMD.O
0.62%Positive
The earnings call reflects a mixed sentiment. Positive aspects include strong revenue growth, raised earnings guidance, and increased cash flow. However, concerns arise from potential FDA clearance delays, regulatory expenses, and competitive pressures. The Q&A reveals uncertainties in growth projections and management's vague responses about the new pump's timeline. Although there are no share repurchase plans, the raised guidance and revenue growth offset some risks. Considering these factors, the stock price is expected to remain stable, resulting in a neutral sentiment.